Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary biliary cholangitis – a chronic, autoimmune disease in which bile ... acid – still a hopeful for NASH despite ...
Iqirvo (elafibranor) is also the first new therapy for PBC in more than a decade, getting a green light as a second-line therapy in combination with ursodeoxycholic acid (UDCA) in adult patients ...
A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...
A new research paper was published in Aging (Aging-US) on February 27, 2025, in Volume 17, Issue 2, titled “Age, sex, and ...
New research reveals that specialized gut bacteria convert bile acids into powerful healing compounds, offering hope for ...
Local News Matters on MSN3d
Nash: Dancing with new parts — Staying in the game when nature says to take a kneeI’VE SPENT THE LAST two summers getting new knees. Total replacements, the right knee in the summer of 2023; the left, in ...
After hours: March 21 at 7:58:33 PM EDT Loading Chart for GLMD ...
Bear bile has been used for thousands of years in traditional Asian medicine. It contains high levels of ursodeoxycholic acid (UDCA) known to be useful for treating liver and gall bladder conditions.
For example, while the ability to synthesise short chain fatty acids (SCFAs) is found in all humans,10 their amounts can vary. A number of dietary strategies are available for modulating either the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback